Sign in
Taking people in Côte d’IvoireNo phase

Testing a rapid blood test for HIV, hepatitis B, hepatitis C and syphilis

Checks how well a point-of-care blood test detects several infections in adults.

Key facts

Who runs it
MagIA Diagnostics
Where
Abidjan, Côte d’IvoireSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)
Status
Recruiting
People taking part
2,950 people, planned
Started
29 Jul 2025
Planned end
Apr 2026
Type of study
Observational
Record updated
2 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who give blood samples to test a new rapid test for HIV, hepatitis B, hepatitis C and syphilis. Samples come from people with and without these infections.

Age
18 years and older
Sex
All sexes
Disease stage
Samples from people who test positive for HIV-1, HIV-2, hepatitis C, hepatitis B or syphilis, or negative samples from donors, clinic patients, vulnerable groups, or people with other conditions that might disturb the test.
Biomarker or test result
Positive samples need at least one: HIV-1 antibody, HIV-2 antibody, HCV antibody, HBsAg, or TPHA positive.

Main reasons for not taking part

  • Samples from people under 18 years of age

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Provide informed consent for participation in this study
  • Patient sample must meet at least one of the criteria below:; Positive samples (serum or plasma) from individuals who meet at least one of the following conditions:
  • HIV-1 Ab positive
  • HIV-2 Ab positive
  • HCV-Ab positive
  • HBsAg positive
  • Positive for at least TPHA, with those positive for both TPHA and VDRL ideally included 2. Negative samples (serum or plasma) from individuals who meet at least one of the following conditions:
  • Blood donors
  • Hospitalized patients or individuals coming to the clinic
  • Vulnerable populations (such as: drug users, prison population, ...) 3. Negative samples (serum or plasma) containing potential interfering substances from individuals who meet at least one of the following conditions:
  • Being a pregnant woman
  • Infected with at least one of the following viruses or bacteria: hepatitis A virus (HAV), hepatitis E virus (HEV), tuberculosis (TB), gonorrhoea, chlamydia, influenza virus, Covid-19
  • Presenting any of the following criteria:; High IgG levels; High rheumatoid factor (>15 IU/mL); High cholesterol levels (>0.24 md/dL); High bilirubin levels (>0.25 mg/mL); High triglyceride levels (>500 mg/dL); Diagnosis of cancer

Who cannot take part

  • Samples from patients below 18 years of age

Where in Côte d’Ivoire

Also in 1 other country, 1 site

  • Centre de Diagnostic et de Recherche sur le SIDA et les autres Maladies Infectieuses - CHU TreichvilleAbidjan, Côte d’IvoireContact: Andre INWOLEY, PrTaking people

About the trial

What the trial wants to find out

Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from serum, plasma samples collected prospectively or retrospectively in Ivory Coast and Kenya.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Performance Evaluation of MagIA In-vitro Diagnostic Medical Device for Multiplex Screening of Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C and Syphilis in Sub-Saharan Africa
Plain-language title
Testing a rapid blood test for HIV, hepatitis B, hepatitis C and syphilisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 February 2026